Abstract 198P
Background
Lenvatinib is oral tyrosine kinase inhibitor (TKI) that has been available for treatment of unresectable hepatocellular carcinoma (uHCC) in Japan since March 2018. We conducted a multicenter prospective observational study to assess overall survival (OS) of lenvatinib treatment in real world practice.
Methods
This study enrolled patients initially receiving lenvatinib for uHCC as systemic therapy who gave informed consent from July 2018 through January 2019. Observation period for each patient was up to 3 years. Kaplan-Meier method was used to estimate OS, and Cox regression analysis was used to explore factors which were associated with OS. The factors were selected with p value <0.05.
Results
A total of 713 patients were registered at 137 clinical sites, and the effectiveness analysis set were 703 patients. Patient background characteristics in 703 patients included median age:73.0 years (25 to 94), male/female: 564/139, weight: <60/≥60 kg :323/380 ,HBV/HCV/alcohol/NAFLD or NASH :137/287/167/88, modified ALBI grade 1/2a/2b/3 :216/199/258/18, BCLC stage A/B/C/D :57/291/332/11, Vp 0/1/2/3/4 :520/31/52/60/22, with/without extrahepatic metastasis :229/450, AFP level <200/≥200 ng/mL :432/240. Treatment history for uHCC was with/without transcatheter arterial chemoembolization (TACE): 513/190, median number of TACE: 3.0 times (1 to 26), with/without TKI pretreatment: 131/572. The initial dose of lenvatinib were labeled dose in 80.5% of patients <60 kg (8 mg) and 68.2% of patients ≥60 kg (12 mg), respectively. The median (range) duration of treatment with lenvatinib was 186.0 days (2-1,099 days). The median OS (95% CI) was 1.38 years (1.29-1.54 years) and the number of deaths was 445 patients. As a result of multivariate analysis, low ECOG-PS, low modified ALBI grade, low AFP level, small number of intrahepatic lesions, no bile duct involvement, no portal vein involvement and no extrahepatic involvement at baseline were associated with longer median OS.
Conclusions
This analysis showed that the effectiveness of lenvatinib in real world practice were consistent with previous reports.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Eisai Co., Ltd.
Funding
Eisai Co., Ltd.
Disclosure
N. Izumi: Financial Interests, Personal, Speaker, Consultant, Advisor: Eisai, Chugai, Takeda, Lily. K. Motoyoshi: Financial Interests, Personal, Full or part-time Employment: eisai. J. Furuse: Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical, Bayer, Eisai, Eli Lilly Japan, MSD, Yakult Honsha, Chugai Pharma, Novartis Pharma, AstraZeneca, Pfizer, Takeda, Taiho Pharmaceutical, Sannofy, Mylan EPD, EA Pharma, Kyowa Hakko Kirin, Daiichi Sankyo, Teijin pharma, Servier Japan, Incy; Financial Interests, Personal, Advisory Board: Fuji film, Mudi Pharma, Onco Therapy Science, Merck Bio, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Chugai Pharma, Astellas, AstraZeneca, Takara bio, Delta-Fly-Pharma, Incyte Japan; Financial Interests, Institutional, Research Grant: Ono Pharmaceutical, MSD, Merck Bio, J-Pharma, Taiho Pharmaceutical, Takeda, Chugai Pharma, AstraZeneca, Yakult Honsha, Eisai, Daiichi Sankyo, Mochida, Sanofy, Sumitomo Dainippon Bayer, Astellas, Incyte Japan; Financial Interests, Personal, Steering Committee Member: Merck Bio, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Astellas, AstraZeneca, Incyte Japan. All other authors have declared no conflicts of interest.
Resources from the same session
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract